Litcius/Paper detail

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China

Xiaohua Wu, Yang Sun, Hongying Yang, Jing Wang, Hanmei Lou, Dan Li, Xiuli Wang, Hui Zhang, Tao Wu, Y. Li, Chunyan Wang, Guiling Li, Yifeng Wang, Dapeng Li, Ying Tang, Mei Pan, Hongyi Cai, Weihu Wang, Bing Yang, Hua Qian, Qiu‐Hong Tian, Desheng Yao, Ying Cheng, Bing Wei, Xiu-Min Li, Tao Wang, Min Hao, Xiaohong Wang, Tiejun Wang, Juntao Ran, Hong Zhu, Lijing Zhu, Xianling Liu, Yunxia Li, Lihong Chen, Qingshan Li, Xiaojian Yan, Fei Wang, Hongbing Cai, Yunyan Zhang, Zhiqing Liang, Funan Liu, Yi Huang, Bairong Xia, Pengpeng Qu, Zhu Genhai, Youguo Chen, Kun Song, Meili Sun, Zhengzheng Chen, Qiang Zhou, Lina Hu, Guzhalinuer Abulizi, Hongyan Guo, Sihai Liao, Yijing Ye, Ping Yan, Tang Qiu, Guoping Sun, Ting Liu, Dongmei Lu, Mingxiu Hu, Zhongmin M Wang, Baiyong Li, Michelle Xia

2024The Lancet102 citationsDOI

Topics & Concepts

BevacizumabMedicineChemotherapyCervical cancerPlaceboOncologyInternal medicineCancerDouble blindRandomized controlled trialSurgeryAlternative medicinePathologyEndometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer Research